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Abstract: Type 1 Diabetes Mellitus (T1D) is associated with accelerated atherosclerosis that is
responsible for high morbidity and mortality. Endothelial hyperpermeability, a feature of endothelial
dysfunction, is an early step of atherogenesis since it favours intimal lipid uptake. Therefore, we tested
endothelial leakage by loading the sera from T1D patients onto cultured human endothelial cells
and found it increased by hyperglycaemic sera. These results were phenocopied in endothelial cells
cultured in a medium containing high concentrations of glucose, which activates inducible nitric
oxide synthase with a consequent increase of nitric oxide. Inhibition of the enzyme prevented high
glucose-induced hyperpermeability, thus pointing to nitric oxide as the mediator involved in altering
the endothelial barrier function. Since nitric oxide is much higher in sera from hyperglycaemic
than normoglycaemic T1D patients, and the inhibition of inducible nitric oxide synthase prevents
sera-dependent increased endothelial permeability, this enzyme might represent a promising
biochemical marker to be monitored in T1D patients to predict alterations of the vascular wall,
eventually promoting intimal lipid accumulation.
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1. Introduction
Type 1 Diabetes Mellitus (T1D) is a multifactorial disease characterized by chronic hyperglycaemia
that arises from a T cell-mediated autoimmune attack of the pancreatic β-cells and culminates with the
suppression of insulin production [1]. The worldwide incidence is rising by 3% per year and the major
risk of mortality is due to cardiovascular complications caused by accelerated atherosclerosis [2,3].
Since the endothelium is the gate-keeper of vascular health, it is not surprising that endothelial
dysfunction is the early event leading to the development of atherosclerotic lesions [4]. Non-laminar
flow, metabolic challenge and inflammatory cytokines model endothelial function [5].In particular„
hyperglycaemia contributes to macrovascular endothelial dysfunction in T1D by activating multiple
pathways through the accumulation of free radicals and glycolytic intermediates, among others [6].
Accordingly, a high percentage of paediatric patients with T1D shows endothelial dysfunction [7]
strictly associated with poor glycaemic control. However, the mechanisms underlying the insurgence
of cardiovascular damage in patients with T1D are not entirely known and, more importantly, there
are no biomarkers for an early diagnosis. In vivo, endothelial dysfunction is defined by the inability
of the artery to sufficiently dilate in response to a transient reduction of flow and is considered an
indirect measure of nitric oxide (NO) released by the endothelium [8]. Considering in vivo, endothelial
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dysfunction is defined by altered NO synthesis, increased expression of inflammatory molecules,
exaggerated generation of reactive oxygen species (ROS) and enhanced permeability of the cell layer [9].
NO is a simple molecule with complex biological activities. It is implicated in the regulation of
many physiological pathways and it is a key player of vascular health, contributing to the maintenance
of vascular tone and exerting anti-platelet, anti-thrombotic and anti-inflammatory properties [10].
Under physiological conditions, NO generated by endothelial NO Synthase (eNOS) represents the main
source of circulating NO [11]. However, NO can be produced in excess in several clinical conditions,
such as inflammation, when inducible NOS (iNOS) is activated by inflammatory stimuli. While low
levels of NO are beneficial to harmonize coagulation, inflammation and vascular tone, high levels of
NO exert detrimental effects, among which is a reversible increase of endothelial permeability [12],
a relevant early event in atherogenesis.
In vivo NO is oxidized to the stable NO products nitrate and nitrite (NOx). A causal relationship
between NO and plasma levels of NOx exists to the point that NOx plasma measurements reflect
NO bioavailability [13]. Circulating high levels of NO have been reported in T1D patients [14,15] as
well as in diabetic rats [16]. A recent meta-analysis discloses a significant increase in NOx levels in
European T1D patients [17]. Interestingly, the high concentration of NO observed in the serum of
paediatric T1D patients is responsible for mediating hyperfiltration and persistent microalbuminuria,
thus linking vascular to glomerular dysfunction in hyperglycaemic conditions [14]. The increment of
NO could be due to the induction of iNOS in phagocytes in response to the release of pro-inflammatory
cytokines [15]. Moreover, an iNOS-induced elevation of circulating NO seems to be strictly correlated
with insulin-resistant states [18].
On these bases, we measured NOx levels in the sera from 36 T1D paediatric patients and 14 healthy
controls. Next, we evaluated the effects of these sera on endothelial permeability.
2. Results
2.1. Serum NOx Levels and Endothelial Permeability Are Not Associated with Increased Glycated Haemoglobin
in T1D Subjects
Since the half-life of NO in the circulation is shorter than 0.1 s, circulating NO metabolites are
assessed as indicators of NO production [13]. We utilized the Griess assay, a method widely used in
epidemiologic studies [19], to measure NOx in the serum from healthy and T1D subjects. We initially
grouped the sera from our T1D patients according to normal or high levels of glycated haemoglobin
(HbA1c), the surrogate biochemical marker of the average glycaemia over a preceding period of
2–3 months. We detected statistically significant higher amounts of NOx in the sera from T1D patients,
independently from the levels of HbA1c (Figure 1A). We then cultured HUVEC with the same sera
(10%) for 24 h to test the endothelial barrier function and found a feeble, albeit not significant, increase of
endothelial permeability in cells incubated with sera from T1D patients with normal or high HbA1c
(Figure 1B).
2.2. Serum NOx Levels and Endothelial Permeability Are Associated with Hyperglycaemia
We then anticipated that the effects of the sera from T1D patients might depend upon high blood
glucose. Therefore, we grouped these sera according to fasting glycaemia and compared the amounts
of NOx in healthy, normo- and hyperglycaemic T1D subjects. Figure 2A shows that levels of NOx were
significantly increased only in the sera obtained from hyperglycaemic subjects (T1D h.g.). The same
result was obtained when we evaluated endothelial permeability in relation to glycaemia. Indeed,
Figure 2B shows that permeability is markedly increased in HUVEC exposed for 24 h to sera from
hyperglycaemic individuals (T1D h.g.), whereas no significant differences exist between sera from
normoglycaemic T1D (T1D n.g.) and healthy subjects (CTR).
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Figure 1. Amounts of NOx in the sera from healthy individuals, T1D patients with normal or high 
HbA1c and the effects of the same sera on endothelial permeability. The sera of patients were grouped 
according to the levels of HbA1c and their effects on HUVEC were compared to those of sera from 
Figure 1. Amounts of NOx in the sera from healthy individuals, T1D patients with normal or high
HbA1c and the effects of the same sera on endothelial permeability. The sera of patients were grouped
according to the levels of HbA1c and their effects on HUVEC were compared to those of sera from
healthy controls. (A) The levels of NOx were measured in the sera from healthy donors (CTR) and T1D
subjects with normal or high HbA1c (T1D normo-HbA1c or T1D hyper-HbA1c). (B) The effect of the
above-described sera on endothelial permeability was evaluated using a Transwell Permeability Assay.
The results are the mean of three experiments in triplicate. ** p < 0.01.
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2.3. High Concentrations of Extracellular Glucose Increase Endothelial NOx Release and Permeability in 
Endothelial Cells  
To get insights into a possible role of high glucose in inducing endothelial permeability, we 
performed experiments on HUVEC exposed to physiological (5.5 mM, CTR) or high (11.1 and 30 mM) 
concentrations of extracellular glucose for 24 h. Bradykinin (10 μM) was used as a positive control 
for endothelial permeability, while lipopolysaccharide (LPS, 10 μg/mL) was the positive control for 
NOx release. L-Glucose (30 mM) was utilized as a control of osmolarity. D-glucose increased 
endothelial release of NOx (Figure 3A) as well as permeability (Figure 3B) in a concentration-
dependent manner, while L-glucose exerted no effects, thus indicating the pivotal role of high 
glucose, and not increased osmolarity, in inflecting endothelial performance. 
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2.3. High Concentrations of Extracellular Glucose Increase Endothelial NOx Release and Permeability in
Endothelial Cells
To get insights into a possible role of high glucose in inducing endothelial permeability,
we performed experiments on HUVEC exposed to physiological (5.5 mM, CTR) or high (11.1 and
30 mM) concentrations of extracellular glucose for 24 h. Bradykinin (10 µM) was used as a positive
control for endothelial permeability, while lipopolysaccharide (LPS, 10 µg/mL) was the positive control
for NOx release. L-Glucose (30 mM) was utilized as a control of osmolarity. D-glucose increased
endothelial release of NOx (Figure 3A) as well as permeability (Figure 3B) in a concentration-dependent
manner, while L-glucose exerted no effects, thus indicating the pivotal role of high glucose, and not
increased osmolarity, in inflecting endothelial performance.
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Figure 3. NOx release and permeability in HUVEC exposed to different concentrations of glucose.
HUVEC were cultured in a medium containing 5 mM (CTR), 11.1 and 30 mM glucose for 24 h. LPS and
Bradykinin were used as positive controls. (A) Media were collected and NOx levels were measured
as described in the methods. (B) Endothelial permeability was studied as described in the methods.
The results are the mean of three experiments in triplicates ± standard deviation (SD). * p < 0.05;
** p < 0.01; *** p < 0.001.
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Figure 4. iNOS and eNOS in HUVEC exposed to different concentrations of glucose. HUVEC were
cultured in a medium containing 5 mM (CTR), 11.1 and 30 mM glucose for 24 h. Western blot was
perfo med using specific antibodies against iNOS (A), P-eNOSSer1177, and eNOS (B). Actin was used
a ma ker of loading. The experim nts were repeated three times and a representative blot is shown.
Densitometry w s perform d by I age J softwar calculating th r tio betwe n the protein of interest
and actin on three separate experi ents ± SD. * p < 0.05.
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We then assessed the role of iNOS and eNOS in modulating endothelial permeability. HUVEC
were pre-treated for 1 h with L-NAME (100 µM) and L-NIL (100 µM), pharmacological inhibitors of
eNOS and iNOS, respectively, and then exposed to a medium containing high concentrations of glucose
for 24 h. In parallel, HUVEC were transiently transfected for 6 h with specific siRNAs targeting iNOS
and eNOS, or a scrambled sequence as a control, and then exposed to high glucose for the following 24 h.
Figure 5 shows that iNOS silencing as well as L-NIL prevented glucose-induced NOx accumulation
and hyperpermeability, whereas L-NAME slightly reduced NOx release and permeability in HUVEC
cultured in high glucose, as expected since eNOS is constitutively active in endothelial cells.
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Figure 5. NOx release and permeability in HUVEC cultured in a medium containing different
concentrations of glucose aft r genetic and pharmacological inhibition of iNOS or eNOS. HUVEC were
cultured in a medium containing 5 mM (CTR), 11.1 and 30 mM glucose for 24 h in the presence of
L-NAME or L-NIL (A,C) or after gene silencing (B,D). A scrambled non silencing sequence was used
as a control (–) for silencing. The results are the mean of three experiments in triplicate ± SD. * p < 0.05;
** p < 0.01; *** p < 0.001.
2.5. Genetic and Pharmacological Inhibition of iNOS Restores Endothelial Permeability in Cells Exposed to Sera
from Hyperglycaemic T1D Patients
We then asked whether the increase of endothelial permeability by sera from hyperglycaemic
T1D patients was dependent upon the induction of iNOS. Endothelial cells were pre-treated for 1 h
with L-NAME (100 µM) or L-NIL (100 µM) before adding to the culture media 10% of T1D serum
from hyperglycaemic or healthy subjects. As shown in Figure 6A, L-NIL reduced endothelial
permeability to approximately the same level as the controls. We also transiently silenced eNOS
and iNOS utilizing specific siRNAs (Figure 6B), while the controls were exposed to a scrambled
sequence. We found a marked reduction of endothelial permeability when a siRNA was used
against iNOS.
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permeability of the endothelium, which favours the accumulation of lipoproteins into the intima 
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expose HUVEC to high extracellular D-glucose to augment their permeability, we anticipate that 
hyperglycaemia is responsible for the increase of endothelial permeability observed when we use 
sera from hyperglycaemic T1D patients. Consistently, high glucose was shown to stimulate 
endothelial transport of dextran through the activation of the Rho signalling pathway, which leads 
to the contraction of the cytoskeleton and the consequent loss of endothelial connections [21]. We 
focused on the identification of the mediators involved in high glucose-induced hyperpermeability 
with the goal of individuating potential biochemical markers that might be useful for the early 
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atherogenesis. Among others, NO modulates endothelial cell permeability in vivo and in vitro [22], 
because it regulates cytoskeletal architecture through Rho [12] and downregulates VE-cadherin [22]. 
Therefore, we evaluated the levels of NOx in the sera from our T1D patients and found a very strong 
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that transient isolated peaks of glycaemia can be detrimental for the integrity of the endothelium 
because they increase permeability by stimulating NO production. This is particularly true in the 
light of the so-called “metabolic memory”, a theory indicating that glycaemic instability promotes 
metabolic and epigenetic changes that remain also when glucose levels return normal [23]. Indeed, 
exposure of HUVEC to oscillating high glucose is more detrimental than constant high glucose and 
induces a metabolic memory after glucose normalization [24]. It is, therefore, important to establish 
a therapeutic/dietetic regimen which keeps glycaemia within the physiological range. 
Figure 6. Permeability in HUVEC cultured in medium containing 10% hyperglycaemic T1D or CTR
sera after genetic and pharmacological inhibition of iNOS or eNOS. HUVEC were cultured in the
presence of sera from healthy and T1D subjects for 24 h with or without L-NAME or L-NIL (A) or
after gene silencing (B). A scrambled non-silencing sequence was used as a control (–) for silencing.
The results are the mean of three experiments in triplicate. ** p < 0.01; *** p < 0.001.
3. Discussion
T1D predisposes to premature atherosclerosis, the main reason for high morbidity and impaired
life expectancy in T1D patients [20]. One of the earliest ev nts in at erogenesis is the elevated
permeability of the endothelium, which favours e accumulation of lipoprot ins into the intima where
they are oxidized and propagate endotheli l dysfunction [4].
Here we show that sera from hyperglycaemic T1D subjects markedly enhance endothelial
leakage, hereas sera from normoglycaemic T1D or healthy individuals do not. Since it suffices to
expose HUVEC to high extracellular D-glucose to augment their permeability, we anticipate that
hyperglycaemia is responsible for the increase of endothelial permeability observed when we use sera
from hyperglycaemic T1D patients. Consistently, high glucose was shown to stimulate endothelial
transport of dextran through the activation of the Rho signalling pathway, which leads to the
contraction of the cytoskeleton and the consequent loss of endothelial connections [21]. We focused
on the identification of the mediators involved in high glucose-induced hyperpermeability with the
goal of individuating potential biochemical markers that might be useful for the early recognition of
alterations of the endothelial barrier and, eventually, become a target to limit and delay atherogenesis.
Among others, NO modulates endothelial cell permeability in vivo and in vitro [22], because it
regulates cytoskeletal architecture through Rho [12] and downregulates VE-cadherin [22]. Therefore,
we evaluated the levels of NOx in the sera from our T1D patients and found a very strong association
between elevated amounts of serum NOx and fasting glucose concentrations. We argue that transient
isolated peaks of glycaemia can be detrimental for the integrity of the endothelium because they
increase permeability by stimulating NO production. This is particularly true in the light of the
so-c lled “metabolic memory”, a theory indicating that glycaemic instability pr mot s metabolic
and pig netic changes that remain also when glucose levels retur normal [23]. Indeed, exposure
of HUVEC to oscillating high glucose is more d trimental than constant high glucose and induces
a metabolic memory after glucose nor al zation [24]. It is, ther fore, important to establish a
therapeutic/dietetic regimen whic keeps glycaemia within the physiologi al range.
While higher amounts of ser m NOx in T1D patients versus controls are reported also
by other authors [17,25], the source of NOx re ains undetermined. T1D is associated with a
pro-inflammatory environment [26,27]. Plasma concentrations of pro-inflammatory cytokines
IL-1β and IL-17A, as well as T cell synthesized cytokines IFN-γ, TNF-α and IL-23, are increased
in T1D subjects [27]. These cytokines activate iNOS and stimulate NO synthesis in various
cell types, including the vascular cells. Accordingly, lung microvascular endothelial cells
cultured in a high glucose-containing medium and then challenged with LPS upregulate
iNOS [28]. However, no evidence is provided that the increased amounts of iNOS is responsible for
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hyperpermeability, since no pharmacological or genetic inhibition was performed [28]. Additionally,
considering the high heterogeneity of the endothelium and the unique features of lung vasculature,
human pulmonary microvascular endothelial cells are likely to behave differently from the
macrovascular endothelial cells used in our experiments [29].
Our results point to a direct effect of high glucose in increasing NOx levels. Indeed, HUVEC cultured
in media containing high glucose release more NOx than controls in a dose-dependent fashion through
the upregulation of iNOS. Accordingly, genetic or pharmacological inhibition of iNOS prevents the
increase of endothelial permeability caused by the sera from hyperglycaemic T1D patients. In agreement
with our findings, in alloxan-induced T1D rats NOx are increased through the overexpression of
iNOS [30]. To this purpose, it is interesting that aerobic exercise significantly decreases iNOS in
pre-diabetic rats [31]. Therefore, physical activity might represent a preventive strategy to control iNOS
expression in T1D patients, thus tempering endothelial damage. Moreover, it should be recalled that,
besides NOS-derived NO, the steady-state systemic NO concentrations are regulated by the dietary
intake of nitrates and nitrites that can be metabolized into bioactive NO via stepwise reductions [32].
Currently, no data are available about tailored nutritional approaches as tools to control NOx levels
and prevent endothelial hyperpermeability in T1D patients [33].
A last point needs to be considered, i.e., the predictive value of measuring HbA1c as a marker to
individuate early alterations of endothelial function. We found increased NOx amounts independently
from HbA1c levels. Interestingly, increased levels of NOx were reported also in patients with T2D,
the most prevalent form of diabetes. Different from our findings in T1D, NOx levels positively correlate
with both HbA1c and fasting glycaemia in T2D individuals [17]. It would be interesting to unveil the
effects of the sera from T2D patients on endothelial permeability and the levels of NOS.
To conclude, although limited by the small number of subjects included in the study, our results
suggest that sporadic transitory peaks of glycaemia in T1D patients lead to the activation of iNOS.
The consequent increase of NOx impairs the endothelial barrier, thus facilitating subendothelial
accumulation of macromolecules that alter the microenvironment of the intima and promote
vascular disease.
4. Materials and Methods
4.1. Study Population
This is a cohort study in which each participant who fulfilled the inclusion criteria was
consecutively enrolled. The study was carried out in 36 paediatric T1D patients (T1D) and in
14 age-matched non-diabetic healthy donors (CTR). Clinical characteristics of T1D patients and
healthy controls are summarized in Table 1. None of the diabetic patients was affected by other
complications, such as retinopathy (evaluated by stereoscopic fundus photography) or neuropathy
(evaluated by nervous conduction velocity and autonomic tests) or was in treatment with other drugs
except insulin. All patients included in the study were nonsmokers; none was taking antioxidant
supplements or drugs with known antioxidant activity. Normal glycated haemoglobin (HbA1c)
is between 4% and 7.5%. Normal glycaemia ranges between 60 and 100 mg/dL, while fasting
hyperglycaemia was defined for values higher than 100 mg/dl. Informed consent was obtained from
all subjects included in the study. Sera were collected at the University of Milan–V. Buzzi Children’s
Hospital. The study was approved by the Buzzi Children’s Hospital (ASST Fatebenefratelli–Sacco,
Milan, Italy) Ethical Committee (2018/ST/143, 9th October 2018, Milano Area 1). All procedures
followed were in accordance with the ethical standards of the responsible committee on human
experimentation (institutional and national) and with the Declaration of Helsinki 1975, as revised
in 2008.
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Table 1. Clinical characteristics of paediatric T1D patients and healthy controls. Among the T1D
patients, 10 were normoglycaemic, 26 hyper-glycaemic, 11 had high levels of HbA1c (>7.5 %) and
25 had levels of HbA1c within the physiological range.
Healthy Subjects (n = 14) Patients (n = 36)
Sex
Male n = 5 n = 12
Female n = 9 n = 24
Age (years)
Mean 12.5 13.8
Range 3.1–23.7 4.0–24.0
Hb1Ac (%)
Mean 5.7 7.15
Range 5.30–6.80 5.10–8.80
PCR (mg/dL)
Mean 0.53 0.71
Range 0.43–0.61 0.20–2.60
Glycaemia (mg/dL)
Mean 102 168.26
Range 89.0–117.0 40.0–350.0
Therapy None MDI (n = 22)CSII (n = 14)
4.2. Cell Culture
Human Umbilical Vein Endothelial Cells (HUVEC) were obtained from the American Type
Culture Collection (ATCC, Manassas, WV, USA) and cultured in medium M199 (Euroclone, Milano,
Italy) with 10% fetal bovine serum (FBS), 1 mM L–Glutamine, 1 mM Sodium Pyruvate, 1 mM
Penicillin–Streptomycin, 5 U/mL Heparin and 150 µg/mL Endothelial Cell Growth Factor on 2%
gelatin-coated dishes [34] added. To test the sera of the participants, FBS was substituted by
10% of serum collected from subjects (CTR) or paediatric diabetic patients (T1D). The cells were
routinely tested for the expression of endothelial markers and used for 6–7 passages. To perform the
experiments, the cells were trypsinized, stained with 0.4% trypan blue solution and counted using a
Luna Automated Cell Counter (Logos Biosystems, Anyang–si, Gyeonggi–do, South Korea). d–glucose
(Sigma–Aldrich, St. Louis, MO, USA) was used at the concentrations of 11.1 mM and 30 mM and
L–glucose (Sigma–Aldrich) was used as a control of osmolarity at the concentration of 30 mM.
Nitric Oxide Synthase (NOS) was inhibited using either small interfering RNA (siRNA) or
pharmacological inhibitors. Subconfluent cells were transfected with siRNA targeting eNOS (NOS3)
[20 nmol, 5′-TTCGAGGGACACCACGTCATACTCA-3′ (Invitrogen Corporation, Carlsbad, CA, USA)]
or iNOS (NOS2A) [20 nmol, 5′-ATCGAATTTGTCAACCAATAT-3′ (Invitrogen)] [35]. Lipofectamine
RNAiMAX was used as a transfection reagent (Invitrogen), according to the manufacturer’s
recommendations. After 6 h, the siRNA transfection medium was replaced with a culture medium
added with 11.1 mM or 30 mM of glucose. The same experimental approach was used with
10% serum collected from CTR or T1D patients. We tested eNOS- and iNOS-silencing using
Real Time PCR (not shown). Alternatively, subconfluent cells were pre-treated with 100 µM
of pharmacological inhibitors of eNOS [L-Nω–Nitroarginine-Methyl-Ester (L-NAME) and iNOS
[N6–(1-Iminoethyl)-l-Lysine (L-NIL) (Sigma–Aldrich) for 1 h. Then, 10% of serum from the cohort or
two different concentrations of glucose were added. The experiment lasted 24 h. All the experiments
were performed in triplicate 3 times.
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4.3. Transwell Permeability Assay
The Transwell Permeability Assay was performed in a 24-well receiver plate with individual
hanging cell culture inserts (Transwell® Permeable Supports, Euroclone, 0.4µm micropores, (Euroclone,
Milano, Italy)). HUVEC were seeded into the inserts and, when confluent, incubated for 24 h with
a medium containing 10% of serum collected from CTR or T1D patients or with a culture medium
containing 11.1 mM or 30 mM glucose. After the treatment, 1 mg/mL Fluorescein isothiocyanate
labelled–albumin (FITC–BSA) (Sigma–Aldrich), a fluorescent probe able to cross the monolayer of
endothelial cells at a rate proportional to the monolayer’s permeability, was added [36]. The extent of
permeability was determined by measuring the fluorescence in the lower compartment. Fluorescence
was detected by the Promega Glomax Multi Detection System at excitation and emission spectrum
wavelengths of 495/519 nm. The experiment was performed in triplicate 2 times.
4.4. NOS Activity
NOS activity was measured in the culture media and in the serum from the patients using the
Griess Assay [19] which measures NO oxidative products (NOx). Briefly, culture media or sera
were mixed with freshly prepared Griess reagent and the absorbance was measured at 550 nm.
The concentration of nitrites in the samples was determined using a calibration curve generated with a
known concentration of sodium nitrite (NaNO2) solutions. The experiment was performed in triplicate
3 times.
4.5. Western Blot Analysis
HUVECs were lysed in 50 mM Tris–HCl (pH 7.4) containing 150 mM NaCl, 1% NP40, 0.25%
sodium deoxycholate, protease inhibitors (10 µg/mL Leupeptin, 10 µg/mL Aprotinin, 1 mM PMSF) and
phosphatase inhibitors (1 mM sodium fluoride, 1 mM sodium vanadate, 5 mM sodium phosphate).
Lysates (40 µg/lane) were separated on SDS–PAGE and transferred to nitrocellulose sheets at 400 mA for
2 h at 4 ◦C. Western Blot analysis was performed using antibodies against iNOS (BD Biosciences, Milano,
Italy), P-eNOSSer1177 (Cell Signaling Technology, Danvers, Massachusetts, USA), eNOS (BD Biosciences)
and Actin (Santa Cruz Biotechnology, Dallas, TX, USA) [37]. After extensive washing, secondary
antibodies labelled with horseradish peroxidase (GE Healthcare, Waukesha, WI, USA) were used.
Immunoreactive proteins were detected by the SuperSignal Chemiluminescence Kit (Thermo Fisher
Scientific Waltham, MA, USA) [35]. The experiment was performed 3 times and quantified using
Image J software (National Institutes of Health, Bethesda, MD, USA).
4.6. Statistical Analysis
Data are reported as means ± SD. The data were normally distributed and they were analyzed
using one-way repeated measures ANOVA. The p-values deriving from multiple pairwise comparisons
were corrected by the Bonferroni method. Statistical significance was defined for p-value ≤ 0.05.
Regarding the Figures, * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001.
5. Conclusions
In this study, we show that sera from hyperglycaemic T1D patients significantly increase endothelial
permeability through the upregulation of iNOS. Therefore, the identification of iNOS as a possible
biomarker that promotes the insurgence of vascular disease in T1D could entail potential planning for
the prevention of cardiovascular complications in T1D.
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Abbreviations
T1D Type 1 diabetes
NO Nitric Oxide
ROS Reactive Oxygen Species
eNOS endothelial Nitric Oxide Synthase
eNOSSer1177 eNOS phosphorylated on Ser1177
iNOS inducible Nitric Oxide Synthase
NOx nitrate and nitrite
Hb1Ac glycated haemoglobin
HUVEC Human Umbilical Vein Endothelial Cells
FBS Fetal Bovine Serum
L-NAME L-Nω–Nitroarginine-Methyl-Ester
L-NIL N6–(1-Iminoethyl)-L-Lysine
LPS lipopolysaccharide
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